BioLargo (BLGO) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024, reached $14.12 million, up 80% year-over-year, with Q3 revenue at $4.4 million, up 63% from the prior year, driven primarily by Pooph-branded product sales.

• Net loss for Q3 was $1.06 million, narrowed from the prior year, with non-cash expenses and investments in R&D and capital equipment contributing to losses.

• Cash and equivalents stood at $3.9 million, with $7.4 million in current assets and a current ratio of 2.3x as of September 30, 2024.

• Focused on commercializing technologies in medical (Clyra), energy (battery tech), odor/VOC control (O&M/POOPH), and water/PFAS equipment, with significant investments in Clyra and battery technology.

• ONM Environmental is the only profitable segment, while other units continue to invest in R&D and commercialization.

Financial highlights

• Q3 2024 revenue was $4.4 million, up 63% year-over-year; nine-month revenue was $14.12 million, up 80% year-over-year.

• Net loss for Q3 was $1.06 million; nine-month net loss was $2.62 million, both improved from prior-year periods.

• Gross profit for Q3 was $1.72 million; nine months: $6.10 million.

• Cash used in operating activities for nine months was $1.29 million; equipment purchases totaled $1.26 million.

• Stockholders' equity reached $6.0 million YTD 2024.

Outlook and guidance

• Targeting over $19 million in annual revenue for 2024, with aspirations for 100% year-over-year growth into 2025.

• Clyra Medical aims for scaled production readiness and launch in Q1 2025, supported by over $1.6 million in equipment investment.

• Pooph brand targets 20% quarter-over-quarter growth, expansion into 80,000 stores, and new product launches.

• Cellinity battery technology expects revenue to begin during development, with factory partnerships projected to generate $60 million per project and 6% royalties.

• Management expects continued need for investment capital to fund business plans and technology commercialization.